CRDF insider transaction filings
Cardiff Oncology, Inc. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-16. Screen CRDF transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 2 insiders — 721,649 shares, $1,049,999 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 687,285 shares @ $1.46 ($1,000,000) by PACE GARY W, filed 2026-07-16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| PACE GARY W — Director | 1 | 1 leg · 687,285 sh · $1,000,000 | — | 1 |
| Mohindru Mani — Chief Executive Officer, Director | 1 | 1 leg · 34,364 sh · $50,000 | — | 1 |
Recent Form 4 filings — Cardiff Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-16 | 4 | Mohindru Mani — Chief Executive Officer, Director | Purchase (P): 34,364 @ $1.46 · Purchase (P): 34,364 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | PACE GARY W — Director | Purchase (P): 687,285 @ $1.46 · Purchase (P): 687,285 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Mohindru Mani — Chief Executive Officer, Director | Purchase (P): 24,703 @ $1.21 | EDGAR |
| 2026-06-22 | 4 | PACE GARY W — Director | Purchase (P): 30,000 @ $1.22 | EDGAR |
| 2026-06-15 | 4 | White Lale — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | TANNENBAUM RENEE P — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Markin Rodney S — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Armitage James O — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | PACE GARY W — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Aggarwal Ajay — Chief Operating Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Smeal Tod — Chief Scientific Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Muntner Joshua B — Chief Financial Officer | Grant/award (A): 486,650 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4/A | Muntner Joshua B — Chief Financial Officer | Grant/award (A): 486,650 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Mohindru Mani — Chief Executive Officer, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Lindsay Brigitte Ute — Chief Accounting Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Mohindru Mani — Interim CEO, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | PACE GARY W — Director | Purchase (P): 275,000 @ $2.45 · Purchase (P): 15,000 @ $2.45 | EDGAR |
| 2025-06-30 | 4 | TANNENBAUM RENEE P — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Markin Rodney S — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Mohindru Mani — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Armitage James O — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | White Lale — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | PACE GARY W — Director | Grant/award (A): 40,565 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Kabbinavar Fairooz — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Levine James E. — Chief Financial Officer | Grant/award (A): 332,621 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Smeal Tod — Chief Scientific Officer | Grant/award (A): 332,621 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Erlander Mark — Chief Executive Officer, Director | Grant/award (A): 758,400 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Levine James E. — Chief Financial Officer | Purchase (P): 2,564 @ $3.83 · Purchase (P): 2,752 @ $5.42 · Purchase (P): 2,400 @ $5 | EDGAR |
| 2024-12-16 | 4 | TANNENBAUM RENEE P — Director | Purchase (P): 10,000 @ $3.42 | EDGAR |
| 2024-12-12 | 4 | PACE GARY W — Director | Purchase (P): 350,115 @ $2.60 · Purchase (P): 11,500 @ $2.60 | EDGAR |
| 2024-07-01 | 4 | White Lale — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | TANNENBAUM RENEE P — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Mohindru Mani — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Armitage James O — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Markin Rodney S — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | PACE GARY W — Director | Grant/award (A): 29,700 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Levine James E. — Chief Financial Officer | Grant/award (A): 205,008 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Kabbinavar Fairooz — Chief Medical Officer | Grant/award (A): 205,008 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Smeal Tod — Chief Scientific Officer | Grant/award (A): 205,008 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Erlander Mark — Chief Executive Officer, Director | Grant/award (A): 510,000 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | PACE GARY W — Director | Purchase (P): 30,000 @ $1.37 | EDGAR |
Recent 8-K events — Cardiff Oncology, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRDF returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →